Efficacy and safety of ajmaline in patients with electrical storm
In selected patients with refractory ES, intravenous ajmaline treatment was associated with a reduction in ventricular arrhythmias and a favorable safety profile. Ajmaline may serve as a valuable bridge to definitive treatment in life-threatening ES.
Authors
- Julian Wolfes (ORCID: https://orcid.org/0000-0002-9344-7826)
- Lars Eckardt (ORCID: https://orcid.org/0000-0002-3735-8503)
- Benjamin Rath (ORCID: https://orcid.org/0000-0002-2516-2394)
- Gerrit Frommeyer (ORCID: https://orcid.org/0000-0002-1431-9886)
- Hilke Könemann (ORCID: https://orcid.org/0000-0002-9812-5519)
- Fabienne Kreimer (ORCID: https://orcid.org/0000-0003-1400-6254)
- Fatih Güner
- Julia Köbe (ORCID: https://orcid.org/0000-0002-5877-352X)
- Jan Sackarnd
- Antonius Büscher (ORCID: https://orcid.org/0000-0003-1774-4252)
- Antonia Camu
- Christian Ellermann (ORCID: https://orcid.org/0000-0002-9172-296X)
Institutions
- University Hospital Münster (DE)
Publication Details
- Journal
- Heart Rhythm
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.hrthm.2025.12.023
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- Sanofi
- Boston Scientific Corporation
- Bayer HealthCare
- Deutsche Forschungsgemeinschaft
- Deutsche Herzstiftung